26 March 2020  
EMA/CHMP/133160/2020  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Ruconest 
conestat alfa 
On 26 March 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion 
recommending a change to the terms of the marketing authorisation for the medicinal product Ruconest. 
The marketing authorisation holder for this medicinal product is Pharming Group N.V. 
The CHMP adopted an extension to the existing indication to include children from the age of 2 years and 
above. 
For information, the full indication for Ruconest will be as follows: 2 
Ruconest is indicated for treatment of acute angioedema attacks in adults, adolescents, and 
children (aged 2 years and above) with hereditary angioedema (HAE) due to C1 esterase 
inhibitor deficiency. 
Detailed recommendations for the use of this product will be described in the updated summary of product 
characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), 
and will be available in all official European Union languages after a decision on this change to the marketing 
authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days 
from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
 
 
